Speaking at the launch, Steven Fang, Group CEO, CordLife Ltd, “The new CordLife facility in India is by far our most advanced built to date. It was built in line with world-class quality marks such as the American Association of Blood Banks, Therapeutic Goods Administration and ISO. Our investment in these standards is a necessary requirement to support stem cell therapies globally. We are confident that the applications of cord blood stem cells will grow in India."
Cord blood, with its rich source of non-controversial blood stem cells, can be used to treat over 80 diseases today; including certain cancers such as leukaemia and breast cancer, blood disorders like thalassemia major and other immunodeficiencies. A boy with leukaemia was saved after receiving his sibling"s cord blood stem cells which were collected and processed by CordLife Singapore. CordLife Indonesia recently released six cord blood units for the successful clinical treatment of second degree burn trauma patients. Heart patients in the Netherlands also benefited from CordLife"s support. The future looks bright as researchers worldwide continue to unlock the potential of stem cells especially in the field of regenerative medicine.
OneIndia News (With inputs from Agencies)